• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Argenx Se ADR (NQ: ARGX )

    536.88 +0.54 (+0.10%)
    Streaming Delayed Price Updated: 10:24 AM EDT, Sep 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 23,786
    Open 537.05
    Bid (Size) 535.77 (1)
    Ask (Size) 536.54 (2)
    Prev. Close 536.34
    Today's Range 533.26 - 537.05
    52wk Range 327.73 - 554.74
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
    From argenx SE
    Via GlobeNewswire
    Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
    Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows... 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    +40.91%
    +40.91%
    1 Month
    +2.46%
    +2.46%
    3 Month
    +38.42%
    +38.42%
    6 Month
    +35.28%
    +35.28%
    1 Year
    +4.45%
    +4.45%

    More News

    Read More
    argenx to Present at Upcoming Investor Conferences
    From argenx SE
    Via GlobeNewswire
    What 25 Analyst Ratings Have To Say About argenx
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    The Analyst Verdict: argenx In The Eyes Of 27 Experts
    Via Benzinga
    Breaking Down argenx: 12 Analysts Share Their Views
    Via Benzinga
    This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
    Via Benzinga
    Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
    From argenx SE
    Via GlobeNewswire
    argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
    From argenx SE
    Via GlobeNewswire
    argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
    From argenx SE
    Via GlobeNewswire
    Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
    From Zai Lab Limited
    Via Business Wire
    argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
    From argenx SE
    Via GlobeNewswire
    Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
    Via Benzinga
    Exposures Product Safety
    Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
    Via Investor's Business Daily
    Exposures Product Safety
    Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
    From argenx SE
    Via GlobeNewswire
    argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
    From argenx SE
    Via GlobeNewswire
    argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
    From argenx SE
    Via GlobeNewswire
    After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
    Via Investor's Business Daily
    Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
    Via Benzinga
    Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
    Via Investor's Business Daily
    Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.